title: Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?
authors.affiliation: Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy luigi.celio@istitutotumori.mi.it.
authors.forename: Luigi
authors.initials: L
authors.lastname: Celio
authors.affiliation: Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
authors.affiliation: Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
authors.forename: Matti
authors.initials: M
authors.lastname: Aapro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D009025:Morpholines; D003907:Dexamethasone